Labopharm Reports Results for Third Quarter F...(---------------------- FINANCING ACTI...),Health

FINANCING ACTIVITIES

Repayment of capital lease

obligations (24) (21) (71) (61)

Repayment of long-term debt (1,004) (903) (3,061) (2,307)

Proceeds from issuance of

capital stock - 120 225 114,664

Issuance costs of capital

stock - (1,456) - (9,240)

-------------------------------------------------------------------------

(1,028) (2,260) (2,907) 103,056

-------------------------------------------------------------------------

Foreign exchange loss on

cash held in foreign

currencies (207) (12) (1,121) (9)

Net decrease in cash and

cash equivalents during

the period (815) (79,161) (4,653) (4,764)

Cash and cash equivalents,

beginning of period 9,884 94,679 13,722 20,282

-------------------------------------------------------------------------

Cash and cash equivalents,

end of period 9,069 15,518 9,069 15,518

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Cash flows include the

following items:

Interest paid 328 483 1,107 1,542

Income taxes paid (received) (430) 31 (902) 145

-------------------------------------------------------------------------

-------------------------------------------------------------------------

CONSOLIDATED BALANCE SHEETS

(Unaudited)

As at As at

'/>"/>